BlackRock, Inc. 13D and 13G filings for Esperion Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Esperion Therapeutics, Inc. ESPR | BlackRock Inc. BLK | 14,265,367 7.300% | 0 (Unchanged) | Filing |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | Esperion Therapeutics, Inc. ESPR | BlackRock Inc. BLK | 14,265,367 7.300% | 9,620,008 (+207.09%) | Filing |
| 2023-06-08 1:25 pm Sale | 2023-05-31 | 13G | Esperion Therapeutics, Inc. ESPR | BlackRock Inc. BLK | 4,645,359 4.900% | -863,828 (-15.68%) | Filing |
| 2023-02-07 1:06 pm Purchase | 2022-12-31 | 13G | Esperion Therapeutics, Inc. ESPR | BlackRock Inc. BLK | 5,509,187 7.500% | 3,267,970 (+145.81%) | Filing |
| 2022-01-10 12:54 pm Purchase | 2021-12-31 | 13G | Esperion Therapeutics, Inc. ESPR | BlackRock Inc. BLK | 2,241,217 3.600% | 177,012 (+8.58%) | Filing |
| 2021-02-05 07:51 am Sale | 2020-12-31 | 13G | Esperion Therapeutics, Inc. ESPR | BlackRock Inc. BLK | 2,064,205 7.400% | -4,027 (-0.19%) | Filing |